Biomea Fusion Inc

NASDAQ BMEA

Data sourced from

and

Download Data

Biomea Fusion Inc Free Cash Flow to Firm (FCFF) for the Trailing 12 Months (TTM) ending March 31, 2024

Biomea Fusion Inc Free Cash Flow to Firm (FCFF) is NA for the Trailing 12 Months (TTM) ending March 31, 2024. Free Cash Flow to Firm represents the cash flow available to all capital providers, including both equity and debt holders. It considers the tax shield effect of interest expense. This ratio indicates the company's ability to generate cash flow available to all stakeholders, including interest payments to debt holders and returns to equity shareholders.

Biomea Fusion Inc Free Cash Flow to Firm (FCFF) for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -77.42 M, a -669.91% change year over year.
Biomea Fusion Inc Free Cash Flow to Firm (FCFF) for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -10.06 M.

NASDAQ: BMEA

Biomea Fusion Inc

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road, Redwood City, CA, United States, 94063
Employees	110
Sector	Healthcare
Industry	Biotechnology

Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends